Cargando…
ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids
SIMPLE SUMMARY: Ovarian cancer (OvCa) treatment is still a challenge, mainly due to acquired resistance mechanisms during the course of chemotherapy. Here, we show the enhanced cytotoxicity of the combined treatment with the ADAM17 inhibitor GW280264X and cisplatin in comparison with cisplatin monot...
Autores principales: | Hedemann, Nina, Herz, Andreas, Schiepanski, Jan Hendrik, Dittrich, Jan, Sebens, Susanne, Dempfle, Astrid, Feuerborn, Julia, Rogmans, Christoph, Tribian, Nils, Flörkemeier, Inken, Weimer, Jörg, Krüger, Sandra, Maass, Nicolai, Bauerschlag, Dirk O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122950/ https://www.ncbi.nlm.nih.gov/pubmed/33922533 http://dx.doi.org/10.3390/cancers13092039 |
Ejemplares similares
-
Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages
por: Rogmans, Christoph, et al.
Publicado: (2022) -
ADAM17—A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer
por: Rogmans, Christoph, et al.
Publicado: (2021) -
Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
por: Flörkemeier, Inken, et al.
Publicado: (2022) -
Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non‐invasive vaginal swab
por: Weimer, Jörg, et al.
Publicado: (2023) -
High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer
por: Flörkemeier, Inken, et al.
Publicado: (2021)